WO2017193186A1 - Composições cosméticas para reparação cutânea - Google Patents
Composições cosméticas para reparação cutânea Download PDFInfo
- Publication number
- WO2017193186A1 WO2017193186A1 PCT/BR2016/050362 BR2016050362W WO2017193186A1 WO 2017193186 A1 WO2017193186 A1 WO 2017193186A1 BR 2016050362 W BR2016050362 W BR 2016050362W WO 2017193186 A1 WO2017193186 A1 WO 2017193186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- mmp
- treatment
- regeneration
- repair
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000002537 cosmetic Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 244000205479 Bertholletia excelsa Species 0.000 claims abstract description 18
- 235000012284 Bertholletia excelsa Nutrition 0.000 claims abstract description 18
- 230000036560 skin regeneration Effects 0.000 claims abstract description 15
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 8
- 206010013786 Dry skin Diseases 0.000 claims abstract description 6
- 230000037336 dry skin Effects 0.000 claims abstract description 6
- 230000007246 mechanism Effects 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 230000008439 repair process Effects 0.000 claims description 23
- 241000712486 Fevillea trilobata Species 0.000 claims description 16
- 230000004663 cell proliferation Effects 0.000 claims description 16
- 230000035876 healing Effects 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 15
- 108090000695 Cytokines Proteins 0.000 claims description 15
- 230000012292 cell migration Effects 0.000 claims description 14
- 238000011002 quantification Methods 0.000 claims description 13
- 102100027995 Collagenase 3 Human genes 0.000 claims description 12
- 108050005238 Collagenase 3 Proteins 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 12
- 108090000174 Interleukin-10 Proteins 0.000 claims description 12
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 12
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 108010065805 Interleukin-12 Proteins 0.000 claims description 11
- 102000013462 Interleukin-12 Human genes 0.000 claims description 11
- 108090001005 Interleukin-6 Proteins 0.000 claims description 11
- 102000004889 Interleukin-6 Human genes 0.000 claims description 11
- 108090001007 Interleukin-8 Proteins 0.000 claims description 10
- 102000004890 Interleukin-8 Human genes 0.000 claims description 10
- 102000016942 Elastin Human genes 0.000 claims description 9
- 108010014258 Elastin Proteins 0.000 claims description 9
- 229920002549 elastin Polymers 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000008929 regeneration Effects 0.000 claims description 8
- 238000011069 regeneration method Methods 0.000 claims description 8
- 102000000589 Interleukin-1 Human genes 0.000 claims description 7
- 108010002352 Interleukin-1 Proteins 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 6
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 6
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 6
- 230000033077 cellular process Effects 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000005012 migration Effects 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- 238000007634 remodeling Methods 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 102000013382 Gelatinases Human genes 0.000 claims description 4
- 108010026132 Gelatinases Proteins 0.000 claims description 4
- -1 IL- 1 B Proteins 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000037390 scarring Effects 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 36
- 239000003921 oil Substances 0.000 description 35
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 10
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 9
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 9
- 235000009321 Pouteria lucuma Nutrition 0.000 description 9
- 244000266507 Pouteria lucuma Species 0.000 description 9
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940090813 madecassoside Drugs 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 229940126864 fibroblast growth factor Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 5
- 101150021185 FGF gene Proteins 0.000 description 5
- 108090000526 Papain Proteins 0.000 description 5
- 229960000458 allantoin Drugs 0.000 description 5
- 229940055729 papain Drugs 0.000 description 5
- 235000019834 papain Nutrition 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009442 healing mechanism Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020113 brazil nut Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000030393 positive regulation of fibroblast proliferation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to skin-repairing cosmetic compositions comprising at least one oil selected from Bertholletia excelsa or Fevillea trilobata and cosmetically acceptable excipients, as well as their use and methods for skin regeneration and healing, providing anti-aging treatment, treatment. of sensitized skin after aesthetic procedures and dry skin, by modulating cellular processes involved in the mechanisms of skin regeneration and healing. It also contemplates an in vitro method for skin repair evaluation.
- the skin has the enormous ability to constantly regenerate. On average, every 28 days a cell walks from the dermo-epidermal junction to the horn extract and then detaches like a dead cell.
- This ability to regenerate is substantially compromised by several environmental and physiological factors, such as loss of hydration, action of external agents such as sun, pollutants, air humidity, disease, smoking, direct damage to the surface of the corneal layer (such as burn, abrasions, rupture, etc.).
- Impairment of skin regeneration capacity can also be asserted by aging, as the rate of cell death and regeneration cycle decreases.
- Skin repair takes two forms: regeneration and healing. These are processes classified as inflammatory in nature. When an inflammatory process, which is always a defense mechanism against an offending agent, begins, the triggering mechanisms of healing and regeneration also begin.
- Regeneration can be defined as the process by which cells that have died due to aggression are replaced by cells in the parenchyma of the same organ. And healing occurs through a highly organized and dynamic multi-stage complex process involving several important cell types in restoring and maintaining tissue integrity.
- the process of skin repair can occur even in the absence of visible lesions to the naked eye, for example by micro-lesions occurring after environmental exposure (UV, weather, dryness, aging). It includes the steps of initial signaling (which can be verified by FGF-2 dosage), inflammation (which can be verified by inflammatory cytokine dosage (IL-1 B, IL-6, IL-8JL-10, IL-12 p70), cell migration and proliferation (which can be verified by cell proliferation assays) and remodeling and resolution (which can be verified by MMP-13 dosage or collagenase and elastase enzyme activity).
- initial signaling which can be verified by FGF-2 dosage
- inflammation which can be verified by inflammatory cytokine dosage (IL-1 B, IL-6, IL-8JL-10, IL-12 p70)
- cell migration and proliferation which can be verified by cell proliferation assays
- remodeling and resolution which can be verified by MMP-13 dosage or collagenase and elastase enzyme activity.
- the present invention relates to cosmetic skin repair compositions comprising at least one oil selected from Bertholletia excelsa (known as Brazil nuts) or Fevillea trilobata (known as nhandiroba) and cosmetically acceptable excipients.
- Cosmetic skin repair compositions according to the present invention may be available in different cosmetic forms, including without limitation emulsions, gels, powders, sticks, among others, including cosmetically appropriate vehicles / excipients known in the art. for the chosen cosmetic form.
- compositions provide anti-aging treatment including reduction of wrinkles and promotion of skin's regenerative capacity, promotion of firmness and elasticity, particularly reduced with age, as well as treatment of post-sensitized skin.
- -aesthetic procedures for example hair removal, laser, peeling or dermabrasion, treatment of dry skin (oiliness control).
- compositions according to the present invention are suitable for both facial and body use.
- compositions according to the present invention are proven to be efficient in modulating cellular processes involved in skin repair, particularly in the regeneration and healing mechanisms of the skin, including FGF-2 which signals the onset of the healing process, inflammatory cytokines.
- FGF-2 which signals the onset of the healing process
- IL-1 B, IL-6, IL-8, IL-10, IL-12 cell migration and proliferation associated with skin barrier construction and elastase activity (MMP-12) degrading elastin, MMP-13, glycosaminoglycans and elastin.
- MMP-12 elastase activity
- the present invention also contemplates the use of cosmetic skin repair compositions according to the present invention and methods related to the cosmetic treatment of skin regeneration and healing, particularly by modulating cellular processes involved in skin repair associated with skin regeneration and healing mechanisms, including FGF , IL-1B, IL-6, IL-8, IL-10, IL-12, cell migration and proliferation, elastase activities, MMP-13, glycosaminoglycans and elastin.
- the present invention also contemplates an in vitro method for evaluating skin repair, suitable for the study of various actives, which comprises the following steps:
- Step 1 Initial signaling: FGF-2 growth factor quantification by flow cytometry technique
- Step 2 Inflammation: Quantification of inflammatory cytokines (IL-1 B, IL-6, IL-8, IL-10, IL-12 p70) by flow cytometry technique;
- tissue regeneration (healing) can be divided into four sequential steps that have as their ultimate goal the restoration of cellular architecture and function. Thus, to characterize this process, some key events of each of these steps were defined for their respective in vitro measurement.
- Step 1 Initial signaling: FGF2 growth factor quantification by flow cytometry technique
- Step 2 Inflammation: Quantification of inflammatory cytokines (IL-1 B, IL-6, IL-8JL-10, IL-12 p70) by flow cytometry technique;
- FGFs comprise a family of 22 polypeptides that regulate proliferation, differentiation, migration and survival of different cell types. Their functions are performed by activating four transmembrane receptor tyrosine kinases called FGFR1 -4.
- FGF basic FGF
- Cytokines are small secreted proteins that affect the behavior of immune cells as well as other cells. These include interleukins, lymphokines and some related signaling molecules such as TNF-alpha (tumor necrosis factor-alpha) and interferons. Chemokines (or chemotactic cytokines) comprise a subset of cytokines that stimulate leukocyte chemotaxis and extravasation to sites of injury.
- Proinflammatory cytokines including IL-1 alpha and IL-1 beta,
- IL-6 and TNF-alpha play an important role in lesion repair because they induce biological responses at the lesion site, including stimulation of keratinocyte and fibroblast proliferation, ECM protein synthesis and degradation, fibroblast chemotaxis, and regulation of the immune response. .
- the Production of these cytokines should occur at low levels and should be combined with production of anti-inflammatory cytokines such as IL-10, the major cytokine responsible for resolving the inflammatory process at the site of injury. Corroborating this information, all increases observed for proinflammatory cytokines in this study represented low but significant levels and were combined with the observation of increased antiinflammatory cytokine IL-10.
- MMP-1 Colaaenase
- MMP-2 Collagen IV Elastase
- MMP-12 Elastase
- Quantification of MMP-13 Colaaenase III
- the proteins that make up the extracellular matrix include collagen, adhesive glycoproteins (fibrulin, fibrillin, elastin), proteoglycans, among others. Through structural domains, these proteins promote biological activities, modulate the activity of growth factors and cytokines and comprise recognition sites for interaction with specific cell membrane receptors. These proteins form a structural scaffold in all tissues, interacting with each other in building large structural networks. The synthesis, deposition and remodeling of these proteins are essential for restoration of damaged tissues during healing.
- Collagen represents the most abundant protein in our body, with literature describing at least 19 different types of collagen. In the skin, collagen is predominantly type I and III occurring in a 4: 1 ratio and is responsible for maintaining skin structure, strength and integrity. Type IV collagen is a component of the endothelial and epidermal basement membranes.
- collagen III predominates, which is replaced by collagen I in the later stages.
- MMP-1 1 and MMP-13 are released by endothelial cells and fibroblasts, which allows these cells to migrate, while macrophage and neutrophil proteases remove degraded matrix components promoting remodeling of repaired tissue.
- Bertholletia excelsa and / or Fevillea trilobata oils have biological activity related to skin regeneration / repair (Table 1), similar to that observed for some patterns like madecassoside. Comparatively, Bertholletia excelsa oil still had a higher potential for modulating this activity than Fevillea trilobata oil.
- these oils may be associated with products indicated for sensitized skin after aesthetic procedures, damaged skin (with microlesions), dry skin or even anti-aging, since there is a gradual reduction of the regenerative capacity of the skin with the advancement of skin. age.
- compositions according to the present invention are proven (in vitro) efficient in modulating cellular processes involved in skin repair, particularly in skin regeneration and healing mechanisms, including FGF-2, IL inflammatory cytokines. -1 B, IL-6, IL-8, IL-10, IL-12, cell migration and proliferation and elastase activity (MMP-12), MMP-13, glycosaminoglycans and elastin, providing anti-aging effect, including reduction of wrinkles and promotion of skin regenerative capacity, firmness and elasticity, as well as treatment of sensitized skin after aesthetic procedures, and dry or damaged skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/301,159 US20190282492A1 (en) | 2016-05-12 | 2016-12-29 | Cosmetic compositions for skin reparation |
EP16901174.9A EP3456313A4 (en) | 2016-05-12 | 2016-12-29 | COSMETIC COMPOSITIONS FOR SKIN REPAIR |
MX2018013860A MX2018013860A (es) | 2016-05-12 | 2016-12-29 | Composiciones cosmeticas para reparacion cutanea. |
BR112018073287A BR112018073287A2 (pt) | 2016-05-12 | 2016-12-29 | composições cosméticas para reparação cutânea |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662335397P | 2016-05-12 | 2016-05-12 | |
US62/335,397 | 2016-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017193186A1 true WO2017193186A1 (pt) | 2017-11-16 |
Family
ID=60266045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2016/050362 WO2017193186A1 (pt) | 2016-05-12 | 2016-12-29 | Composições cosméticas para reparação cutânea |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190282492A1 (pt) |
EP (1) | EP3456313A4 (pt) |
AR (1) | AR107263A1 (pt) |
BR (1) | BR112018073287A2 (pt) |
CL (1) | CL2018003212A1 (pt) |
MX (1) | MX2018013860A (pt) |
WO (1) | WO2017193186A1 (pt) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019023774A1 (pt) * | 2017-07-31 | 2019-02-07 | Natura Cosméticos S.A. | Complexo cosmético para hidratação bioativa, composição cosmética, uso e método |
WO2020206515A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Composição cosmética tópica e usos da mesma |
WO2020206514A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Complexo cosmético e usos do mesmo |
WO2020206513A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Uso do óleo de fevillea trilobata |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LV15615B (lv) * | 2021-11-30 | 2023-02-20 | Rīgas Stradiņa Universitāte | Krēms roku ādas epidermālās lipīda barjeras aizsardzībai un nostiprināšanai, gadījumos, kad āda tiek pakļauta biežai dezinfekcijas līdzekļu iedarbībai |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0853360A (ja) * | 1994-06-10 | 1996-02-27 | Suntory Ltd | ヒスタミン遊離抑制剤並びにこれを含有する化粧品及び食品 |
US6004568A (en) * | 1995-02-17 | 1999-12-21 | Lvmh Recherche | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract |
US20030059484A1 (en) * | 1996-11-07 | 2003-03-27 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
US6596287B2 (en) * | 1997-05-27 | 2003-07-22 | Semibiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US20120071263A1 (en) * | 2008-05-16 | 2012-03-22 | Taylor Made Golf Company, Inc. | Golf club |
US20160058689A1 (en) * | 2014-08-28 | 2016-03-03 | Natura Cosméticos S.A. | Compositions for Cosmetic Formulation Comprising A Mixture Selected From Murumuru Butter, Ucuúba Butter, Brazilian-Nut Oil, Passion Fruit Oil, Cupuassu Butter, Assaí Oil and / or Nhandiroba Oil and / or Esters Therefor, As Well As The Use Of A Mixture for Preparation Of A Cosmetic Product |
-
2016
- 2016-12-29 BR BR112018073287A patent/BR112018073287A2/pt not_active Application Discontinuation
- 2016-12-29 US US16/301,159 patent/US20190282492A1/en not_active Abandoned
- 2016-12-29 MX MX2018013860A patent/MX2018013860A/es unknown
- 2016-12-29 WO PCT/BR2016/050362 patent/WO2017193186A1/pt active Search and Examination
- 2016-12-29 AR ARP160104076A patent/AR107263A1/es unknown
- 2016-12-29 EP EP16901174.9A patent/EP3456313A4/en not_active Withdrawn
-
2018
- 2018-11-12 CL CL2018003212A patent/CL2018003212A1/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0853360A (ja) * | 1994-06-10 | 1996-02-27 | Suntory Ltd | ヒスタミン遊離抑制剤並びにこれを含有する化粧品及び食品 |
US6004568A (en) * | 1995-02-17 | 1999-12-21 | Lvmh Recherche | Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract |
US20030059484A1 (en) * | 1996-11-07 | 2003-03-27 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
US6596287B2 (en) * | 1997-05-27 | 2003-07-22 | Semibiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US20120071263A1 (en) * | 2008-05-16 | 2012-03-22 | Taylor Made Golf Company, Inc. | Golf club |
US20160058689A1 (en) * | 2014-08-28 | 2016-03-03 | Natura Cosméticos S.A. | Compositions for Cosmetic Formulation Comprising A Mixture Selected From Murumuru Butter, Ucuúba Butter, Brazilian-Nut Oil, Passion Fruit Oil, Cupuassu Butter, Assaí Oil and / or Nhandiroba Oil and / or Esters Therefor, As Well As The Use Of A Mixture for Preparation Of A Cosmetic Product |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019023774A1 (pt) * | 2017-07-31 | 2019-02-07 | Natura Cosméticos S.A. | Complexo cosmético para hidratação bioativa, composição cosmética, uso e método |
US11260021B2 (en) | 2017-07-31 | 2022-03-01 | Natura Cosméticos S.A. | Cosmetic complex for bioactive hydration, cosmetic composition, use and method |
WO2020206515A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Composição cosmética tópica e usos da mesma |
WO2020206514A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Complexo cosmético e usos do mesmo |
WO2020206513A1 (pt) * | 2019-04-11 | 2020-10-15 | Natura Cosméticos S.A. | Uso do óleo de fevillea trilobata |
EP3954358A4 (en) * | 2019-04-11 | 2023-03-01 | Natura Cosméticos S.A. | COSMETIC COMPLEX AND USES OF IT |
EP3954359A4 (en) * | 2019-04-11 | 2023-03-01 | Natura Cosméticos S.A. | TOPICAL COSMETIC COMPOSITION AND USES THEREOF |
Also Published As
Publication number | Publication date |
---|---|
EP3456313A1 (en) | 2019-03-20 |
CL2018003212A1 (es) | 2019-02-15 |
BR112018073287A2 (pt) | 2019-02-19 |
AR107263A1 (es) | 2018-04-11 |
US20190282492A1 (en) | 2019-09-19 |
EP3456313A4 (en) | 2020-09-23 |
MX2018013860A (es) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017193186A1 (pt) | Composições cosméticas para reparação cutânea | |
BR112017008726B1 (pt) | Usos de um extrato de fermento e de um exopolissacarídeo, e, composição cosmética | |
JP5896916B2 (ja) | アクアポリンの発現を活性化するための活性薬剤としてイナゴマメの抽出物を含む、化粧品組成物および/または医薬組成物 | |
CN104667335A (zh) | 皮肤屏障功能或痔的重组人源胶原蛋白产品及制备方法 | |
CN107619437A (zh) | 一种皮肤创伤修复肽whpp‑oa1及其提纯方法与应用 | |
CN110833516A (zh) | 一种具有补水保湿作用的多肽组合物 | |
US6193975B1 (en) | Use of potentilla erecta extract in the cosmetic and pharmaceutical field | |
WO2017011983A1 (zh) | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 | |
DE60212143T2 (de) | Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera | |
BR112019022610A2 (pt) | utilização cosmética de um extrato de nephelium lappaceum, método de cuidado cosmético, e, extrato | |
CN116672296B (zh) | 具有舒缓修护功效的复方植物提取物、其制备方法及应用 | |
CN111420023B (zh) | 含i型胶原和透明质酸的复合物及制备和用途 | |
RU2665371C2 (ru) | Синергетическая комбинация аланин-глутамина, гиалуроновой кислоты и экстракта овса и ее применение в композиции для заживления ран и восстановления повреждений кожи | |
EP2101879A2 (en) | Cosmetic composition for the treatment and/or prevention of skin stretch marks | |
ES2699239T3 (es) | Utilización cosmética de un extracto de Harungana madagascariensis | |
Jeon et al. | Effects of high voltage pulsed current stimulation with a visible contraction intensity on expression of TGF-β1 and synthesis of type I collagen in wound-induced white rats | |
Walters et al. | Skin Morphology, Development and Physiology | |
WO2018032075A1 (pt) | Composição cosmética antissinais, uso da composição e método para tratamento antissinais | |
CH706016A2 (de) | Auf Stammzellen der Epidermis und Dermis und auf deren Mikro-Umgebung wirkende kosmetische Zusammensetzung. | |
CN107320356A (zh) | 一种胶原紧致精华 | |
DE3147727C2 (de) | Wundheilmittel enthaltend Kollagen aus Basalmembranen | |
KR101975938B1 (ko) | 금사연 둥지 추출물 및 후코이단을 유효성분으로 포함하는 피부 건조증 개선용 조성물 | |
EP3471835B1 (en) | Use of extracts of deschampsia antartica for counteracting human skin barrier damage caused by environmental aggressions. | |
KR19980033891A (ko) | 홍삼 지질 추출액 조성물 및 그 피부 항노화제의 용도 | |
Khalid et al. | Anti-Aging Topical Peptides and Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018073287 Country of ref document: BR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16901174 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016901174 Country of ref document: EP Effective date: 20181212 |
|
ENP | Entry into the national phase |
Ref document number: 112018073287 Country of ref document: BR Kind code of ref document: A2 Effective date: 20181112 |